Hydralazine detailed information

Hydralazine detailed information

Clinical data
Routes of administration	Oral, intravenous
ATC code	C02DB02 (WHO)
Pharmacokinetic data
Metabolism	Hepatic
Elimination half-life	2-4 hours
Excretion	Renal
Identifiers
IUPAC name 1-hydrazinophthalazine
CAS Number	86-54-4
PubChem CID	3637
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C8H8N4
Molar mass	160.176 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Hydralazine hydrochloride (1-hydrazinophthalazine monohydrochloride; Apresoline) is a direct-acting smooth muscle relaxant used to treat hypertension by acting as a vasodilator primarily in arteries and arterioles. By relaxing vascular smooth muscle, vasodilators act to decrease peripheral resistance, thereby lowering blood pressure.

Mechanism

Hydralazine works through a cGMP-mediated mechanism, resulting in smooth muscle relaxation.

Clinical Use

Hydralazine is not used as a primary drug for treating hypertension because it elicits a reflex sympathetic stimulation of the heart (the baroreceptor reflex). The sympathetic stimulation may increase heart rate and cardiac output, and may cause angina pectoris or myocardial infarction. Hydralazine may also increase plasma renin concentration, resulting in fluid retention. In order to prevent these undesirable side effects, hydralazine is generally prescribed in combination with a beta-blocker (e.g., propranolol) and a diuretic.

Hydralazine is used to treat severe hypertension, but again, it is not a first line therapy for essential hypertension. However, hydralazine is the first line therapy for hypertension in pregnancy, with methyldopa.

Side effects

Common side effects include:

• Diarrhea
• Compensatory tachycardia due to baroreceptor reflex
• Headache
• Loss of appetite
• Nausea or vomiting
• Pounding heartbeat
• Drug-Induced Lupus Erythematosus

Patients given hydralazine over a peroid of six months may develop a lupus-like syndrome or other immune related diseases that generally are reversible with withdrawal. Hydralazine is differentially acetylated by fast and slow acetylator phenotypes thus incidence of lupus-like disease in slow acetylators.

References

hr:Hidralazin

Template:WikiDoc Sources